METHODS: We retrospectively studied the clinical profiles and outcomes of 111 patients with low risk NMIBC who underwent TURBT between 2006-2016. THP (30mg/30ml) was administered into the bladder immediately after TURBT for 15 minutes, or MMC (20mg/20ml) was administrated for 60 minutes; TURBT alone was performed in the control group. We compared the recurrence-free survivals between groups by the Kaplan-Meier method and Cox regression models. RESULTS: Of the 111 patients, 30 were included in the THP group, 23 in the MMC group, and 58 in the control group. The median follow-up period was 27.0 months. The recurrence-free survival (RFS) rates at 1 year and 3 years, respectively, were 89.3% and 85.4% in the THP group, 95.7% and 85.2% in the MMC group, and 73.4% and 59.7% in the control group (p[0.011, Fig.) . A multivariable Cox regression analysis showed that the instillation of THP and MMC were independently associated with a significant improvement of RFS (Table) .
INTRODUCTION AND OBJECTIVES:
Confocal laser endomicroscopy (CLE) enables dynamic imaging of the cellular structures below the mucosal surface and holds promise in providing real time optical diagnosis and grading of urothelial carcinoma. We presented our initial experience using CLE for the diagnosis of urothelial carcinoma of bladder.
METHODS: 21 patients scheduled to undergo transurethral resection of bladder tumors were recruited. One urologist who had already participated in a computer-based training course performed all the CLEs. After standard white light cystoscopy (WLC), fluorescein was administered intravesically as a contrast dye. A 2.6 mm probe based CLE (Cellvizio, Mauna Kea Technologies) was passed through a 26Fr resectoscope to image normal and abnormal appearing areas. The images were collected with 488 nm excitation at 8 to 12 frames per second. The endomicroscopic images were compared with standard hematoxylin and eosin analysis of transurethral resection of bladder tumor specimens.
RESULTS: Of the 21 recruited patients, 1 had no tumor but inflammation, 2 had carcinoma in situ ( CIS), 7 had low grade tumors, 10 had high grade tumors and 1 had a bladder liomyoma. The overall diagnostic accuracy is 80.9% (17/21) combining CLEþ WLC. 1 inflammation was regarded as CIS, 1 low grade tumor was regarded as high grade and 2 high grade tumors were regarded as low grade.
CONCLUSIONS: CLE is an adoptable technology for novice CLE observers after a training session. CLE demonstrated clear differences between normal mucosa and malignant lesions. However, real-time differentiation between low and high grade tumors, inflammation and cancer, can still be challenging.
INTRODUCTION AND OBJECTIVES: Risk stratification into low-, intermediate-and high-risk groups has been widely used for the management of patients with non-muscle-invasive bladder cancer (NMIBC). Although low-and high-risk groups have been clearly classified, the intermediate-risk group has traditionally included heterogeneous patients which do not fit into either of these groups, resulting in uncertainty regarding its prognosis and adjuvant therapy. Whereas small, Ta low-grade recurrence does not present an immediate danger to the patient, recurrence of high-risk tumors should be early detected during the follow-up of intermediate-risk NMIBC patients. Here, we aimed to substratify intermediate-risk NMIBC patients based on the prediction of high-risk recurrence (HRR).
METHODS: This study included 645 primary NMIBC patients who underwent TURBT at a single institution from 2010 to 2018. Risk stratification was according to the EAU guidelines. Of the 645 patients, 330 patients with intermediate-risk NMIBC were in analysis. HRR was defined as high-risk non-muscle-invasive, muscle-invasive, or metastatic recurrences. Factors predicting HRR were explored using the Cox proportional hazards model. RESULTS: Of the total patients, 146 (44%) patients recurred. HRR was developed in 37 (11%) patients, which included 34 (10%) with high-risk non-muscle-invasive recurrence and three (1%) with muscle invasive recurrence. On multivariate analysis, bladder neck involvement (BNI) (HR 2.84, p [ 0.020) and positive urine cytology (PUC) (HR 3.82, p <0.001) were independent predictors for HRR. The 5-yr HRRfree survival (HRRFS) rate was 71% in 82 (25%) patients with either BNI or PUC. Meanwhile, in 248 (75%) patients without BNI and PUC, the 5-yr HRRFS rate was 93% (p <0.001), and no patient eventually progressed to muscle-invasive disease and died of the disease.
CONCLUSIONS: In intermediate-risk NMIBC, most of the patients without bladder neck involvement and positive urine cytology were free from high-risk recurrence. Thus, they may safely avoid adjuvant intravesical therapy and intensive follow-up by cystoscopy.
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MP43-20 SINGLE-DOSE PERIOPERATIVE MITOMYCIN VS. THIOTEPA AFTER TRANSURETHRAL RESECTION OF LOW GRADE NON-INVASIVE BLADDER CANCER
INTRODUCTION AND OBJECTIVES: Mitomycin C (MMC) and
Thiotepa are two intravesical agents that are effective in reducing recurrence in the perioperative management of low grade, non-invasive bladder cancer. There are few data comparing the efficacy between these two agents and no studies comparing these agents in the context of single-dose perioperative instillation. Herein we performed the first comparative study to test the hypothesis that a single perioperative intravesical MMC instillation provides longer cancer free intervals than Thiotepa.
METHODS: This is a retrospective study that reviewed the charts of patients who underwent a cystoscopic bladder mass excision for a small, low grade, treatment-naïve, noninvasive, wild-type urothelial carcinoma of the bladder and received either intravesical Thiotepa (30mg/15cc) or Mitomycin (40mg/20cc) between 2002 Mitomycin (40mg/20cc) between -2016 . Data for demographics, comorbidities, operative information, surveillance, and recurrence was collected. The primary outcome was disease-free survival. The comparison of the average effect between treatment groups was performed by a doubly robust estimation approach that specified both outcome and treatment models simultaneously. RESULTS: In 154 total patients, 84 and 70 patients received intravesical MMC and Thiotepa, respectively. There were no statistically significant differences between the groups with respect to age, gender, race, BMI, smoking status, or baseline comorbidities. There were no statistically significant differences in mass size, tumor multifocality, or tumor grade between the groups. There were no differences in unadjusted (Figure 1 ) recurrence rates (MMC: 36% vs. Thiotepa: 46%, p[0.33) at a similar median length of follow up (MMC: 20.4 vs. Thiotepa: 22.8 months, p[0.46) . A doubly robust estimation was then performed using logistic regression to model the probability of recurrence. This analysis yielded no differences in the recurrence rates between the two groups (OR 0.65; p[0.23) . No episodes of myelosuppression or frozen pelvis were identified in either cohort.
CONCLUSIONS: As single-dose perioperative agents, both Thiotepa and MMC result in similar recurrence free survival rates. Larger prospective studies are needed to confirm the external validity of these observations.
